Search | Clinical Trials Finder

ClinicalTrials.gov public records Last synced Sep 2, 2026, 8:00 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–16 of 16 matching trials from the live ClinicalTrials.gov search.

Local D1 index available.

Filters: Intervention: Finerenone Placebo Clear all

Conditions: Chronic Kidney Disease, Proteinuria
Interventions: Finerenone (Kerendia, BAY94-8862), Placebo; Drug
Lead sponsor: Bayer; Industry
Eligibility: 6 Months to 17 Years
Enrollment: 219 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 10
States / cities: Palo Alto, California • San Diego, California • Hollywood, Florida + 7 more

Conditions: Diabetic Kidney Disease
Interventions: Finerenone (BAY94-8862), Placebo; Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years and older
Enrollment: 7,352 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2021
U.S. locations: 173
States / cities: Birmingham, Alabama • Fort Payne, Alabama • Huntsville, Alabama + 124 more

Conditions: Heart Failure
Interventions: Finerenone (BAY94-8862), Placebo; Drug · Other
Lead sponsor: Bayer; Industry
Eligibility: 40 Years and older
Enrollment: 6,016 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2024
U.S. locations: 107
States / cities: Birmingham, Alabama • Fairhope, Alabama • Mobile, Alabama + 98 more

Conditions: Heart Failure
Interventions: Finerenone (BAY94-8862), Placebo, Inspra (eplerenone); Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years and older
Enrollment: 1,066 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 10
States / cities: Birmingham, Alabama • La Jolla, California • Los Angeles, California + 6 more

Conditions: Chronic Kidney Disease, Type 2 Diabetes
Interventions: Finerenone (Kerendia, BAY94-8862), Sodium-glucose cotransporter-2 inhibitors (SGLT2i); Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years and older
Enrollment: 17,847 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Whippany, New Jersey

Conditions: Diabetic Retinopathy
Interventions: Finerenone (BAY94-8862); Drug
Lead sponsor: Bayer; Industry
Eligibility: Not listed
Enrollment: 206 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 10
States / cities: Chula Vista, California • El Centro, California • Fort Lauderdale, Florida + 7 more

Conditions: Chronic Kidney Disease, Type 1 Diabetes Mellitus
Interventions: Finerenone, Placebo; Drug · Other
Lead sponsor: Bayer; Industry
Eligibility: 18 Years and older
Enrollment: 241 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 28
States / cities: Surprise, Arizona • Stanford, California • Vallejo, California + 22 more

Conditions: Chronic Kidney Disease
Interventions: Finerenone (BAY94-8862), Placebo; Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years and older
Enrollment: 5,734 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2020
U.S. locations: 176
States / cities: Birmingham, Alabama • Fort Payne, Alabama • Huntsville, Alabama + 125 more

Conditions: Type 2 Diabetes Mellitus, Chronic Kidney Disease
Interventions: Finerenone (BAY94-8862 ) 10 mg, Empagliflozin, Empagliflozin Placebo, Finerenone (BAY94-8862 ) 20 mg, Finerenone Placebo; Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years and older
Enrollment: 1,664 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 46
States / cities: Surprise, Arizona • Los Angeles, California • Northridge, California + 36 more

Conditions: Non-diabetic Chronic Kidney Disease
Interventions: Finerenone (BAY94-8862), Placebo; Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years and older
Enrollment: 1,584 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 57
States / cities: Huntsville, Alabama • Chula Vista, California • El Centro, California + 49 more

Conditions: Heart Failure, Acute Heart Failure
Interventions: Finerenone, Placebo; Drug
Lead sponsor: Colorado Prevention Center; Other
Eligibility: 18 Years and older
Enrollment: 5,200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 80
States / cities: Birmingham, Alabama • Fairhope, Alabama • Huntsville, Alabama + 70 more

Conditions: Kidney Transplant; Complications
Interventions: Finerenone Oral Tablet, Placebo; Drug
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Heart Failure
Interventions: Finerenone, Placebo; Drug
Lead sponsor: Colorado Prevention Center; Other
Eligibility: 18 Years and older
Enrollment: 2,600 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 54
States / cities: Fairhope, Alabama • Phoenix, Arizona • Yuma, Arizona + 45 more

Conditions: Chronic Kidney Disease, Type 2 Diabetes Mellitus
Interventions: Finerenone (Kerendia, BAY94-8862), Placebo; Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years and older
Enrollment: 951 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021
U.S. locations: 13
States / cities: Northridge, California • Port Hueneme, California • Waterbury, Connecticut + 9 more

Conditions: Left Ventricular Systolic Dysfunction, Heart Failure (Pediatric)
Interventions: Finerenone (Kerendia, BAY94-8862), Placebo; Drug
Lead sponsor: Bayer; Industry
Eligibility: 6 Months to 17 Years
Enrollment: 111 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 22
States / cities: Aurora, Colorado • Wilmington, Delaware • Gainesville, Florida + 18 more

Conditions: Diabetic Nephropathies
Interventions: Finerenone (BAY94-8862), Placebo; Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years and older
Enrollment: 823 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 15
States / cities: Birmingham, Alabama • Chula Vista, California • Los Angeles, California + 11 more

Search by objective public record fields.

A Study to Learn More About How Well the Study Treatment Finerenone Works, How Safe it is, How it Moves Into, Through, and Out of the Body, and the Effects it Has on the Body When Taken With an ACE Inhibitor or Angiotensin Receptor Blocker in Children With Chronic Kidney Disease and Proteinuria

Efficacy and Safety of Finerenone in Subjects With Type 2 Diabetes Mellitus and the Clinical Diagnosis of Diabetic Kidney Disease

Study to Evaluate the Efficacy (Effect on Disease) and Safety of Finerenone in Participants With Heart Failure and Left Ventricular Ejection Fraction (Proportion of Blood Expelled Per Heart Stroke) Greater or Equal to 40%

Phase IIb Safety and Efficacy Study of Different Oral Doses of BAY94-8862 in Subjects With Worsening Chronic Heart Failure and Left Ventricular Systolic Dysfunction and Either Type 2 Diabetes Mellitus With or Without Chronic Kidney Disease or Chronic Kidney Disease Alone

An Observational Study Called FLAMINgO to Learn More About the Treatment Combination of Finerenone and SGLT2 Inhibitors in People With Long-term Kidney Disease (Chronic Kidney Disease) Together With Type 2 Diabetes by Using Routine Medical Care Data and Past Clinical Study Results

A Study That Uses Data From Routine Eye Examinations of Patients Participating in Studies FIDELIO-DKD and FIGARO-DKD to Explore Whether Finerenone Can Delay the Progression of a Diabetes Complication That Affects the Eyes (Diabetic Retinopathy ,DR)

A Study to Learn How Well the Study Treatment Finerenone Works and How Safe it is in People With Long-term Decrease in the Kidneys' Ability to Work Properly (Chronic Kidney Disease) Together With Type 1 Diabetes

Efficacy and Safety of Finerenone in Subjects With Type 2 Diabetes Mellitus and Diabetic Kidney Disease

A Study to Learn How Well the Treatment Combination of Finerenone and Empagliflozin Works and How Safe it is Compared to Each Treatment Alone in Adult Participants With Long-term Kidney Disease (Chronic Kidney Disease) and Type 2 Diabetes

A Trial to Learn How Well Finerenone Works and How Safe it is in Adult Participants With Non-diabetic Chronic Kidney Disease

A Study to Determine the Efficacy and Safety of Finerenone on Morbidity and Mortality Among Hospitalized Heart Failure Patients

The EFfect of FinErenone in Kidney TransplantiOn Recipients: The EFFEKTOR Study

A Study to Evaluate Finerenone on Clinical Efficacy and Safety in Patients With Heart Failure Who Are Intolerant or Not Eligible for Treatment With Steroidal Mineralocorticoid Receptor Antagonists

An add-on Study to the FIGARO-DKD Study Called FIGARO-BM to Learn About the Link Between Biomarkers (Substances in the Blood Used as Indicators of Biological Processes, Disease Processes or Responses to Medication) and Finerenone in FIGARO-DKD Participants

A Study to Learn More About How Well Finerenone Works, How Safe it is, and How it Moves Into, Through, and Out of the Body Compared to Placebo When Taken With Standard Treatment in Children With Heart Failure and Left Ventricular Systolic Dysfunction

Safety and Efficacy of Different Oral Doses of BAY94-8862 in Subjects With Type 2 Diabetes Mellitus and the Clinical Diagnosis of Diabetic Nephropathy